Avid Bioservices Inc (CDMO)

[cjgaddy]

PPHM’s Bruce Freimark (Dir./ProdDev) speaking 1-30-14 at GTC’s “Novel Immunotherapeutics Summit 2014” in SanDiego. Title: “PS-Targeting Antibodies Enhances Activity of Immune Checkpoint Inhibitors and Re-activates Immune System in Tumors”… http://tinyurl.com/mv5rd8a

Jan30-31 2014: “GTC’s Novel Immunotherapeutics Summit 2014”, SanDiego
Overview: http://www.gtcbio.com/conference/novel-immunotherapeutics-summit-overview
4 Concurrent Sub-Conferences:
• 12th Cytokines & Inflammation
• 6th Immunotherapeutics & Immunomonitoring <=B.Freimark/Bavi
• 2nd Immunogenicity & Immunotoxicity
• Inaugural Innate Immunity
“The immune system plays a central role not only in fighting infections, but also in many other diseases and medical conditions including cancer. The study of the immune system has led to significant findings in many fields of medicine & biology and has resulted in the discovery of novel and unique substances and reagents that are now widely used for diagnosis, evaluation, and therapy of different malignant diseases. The development of prophylactic and therapeutic vaccines, as well as innovative combinatorial immunotherapeutic approaches has substantially decreased mortality and increased life expectancy, improved life expectancy and the well being of the millions of patients. Leading experts from the scientific & clinical arenas and industry will present about novel findings and developments in the constantly changing area of immunological assays and procedures. They will also discuss recent advances in immunotherapy, as they relate to various immunotherapy modalities, specific cancers, cell subsets, animal models, and tumor microenvironment. Potential clinical feasibility and commercial potential of the newest data obtained from leading biomedical research laboratories will also be discussed.”
GTC = GTC Global Technology Community ( http://www.GTCBIO.com )
Agenda: http://www.gtcbio.com/conference/immunotherapeutics-and-immunomonitoring-agenda
Brochure PDF: http://www.gtcbio.com/preview/immunotherapeutics_summit_2014.pdf
- - - - - - - - - - -
6th Immunotherapeutics & Immunomonitoring Conf.
Jan30 Session: “Novel Therapeutics & Targets” (Moderator: Steffen Walter, Immatics Biotech.)
1-30-13 5:25pm: Bruce Freimark, Peregrine Pharm. (PPHM’s Dir./ProdDEV):
“Phosphatidylserine Targeting Antibodies Enhances Activity of Immune Checkpoint Inhibitors and Re-activates Immune System in Tumors”
SUMMARY:
Phosphatidylserine (PS) is a phospholipid normally residing in the inner leaflet of the plasma membrane and becomes exposed on tumor vascular endothelial cells (ECs) and tumor cells. PS exposure becomes enhanced in response to chemotherapy, irradiation, and oxidative stresses in the tumor microenvironment. PS exposure in tumors promotes an immunosuppressive microenvironment which includes the recruitment of myeloid derived suppressor cells, immature dendritic cells, and M2-like tumor associated macrophages as well as the production of anti-inflammatory cytokines. Bavituximab, a chimeric PS-targeting antibody, is being used in combination with chemotherapy to treat patients with solid tumors in multiple late-stage clinical trials. Binding of PS targeting antibodies on tumor ECs, tumor cells and their secreted microparticles increase the presence of M1-like macrophages and cytokine responses that reverse the immunosuppressive PS mediated checkpoint, thereby enhancing anti-tumor immunity. Using multiple tumor models in mice, we demonstrate PS targeting antibodies enhance the anti-tumor activity of multiple forms of therapy including anti-CTLA-4 and anti-PD-1 checkpoint inhibitor antibodies. Tumor growth inhibition correlates with infiltration of immune cells in tumors and induction of adaptive immunity. The combination of these mechanisms promotes strong, localized, anti-tumor responses without the side-effects of systemic immune activation.